Lots to agree with here Tiny. My moderation would be "If the next oncolytic virotherapy deal is not Viralytics, its very bad news"....There are lots of Oncology / I/O deals getting done out there that are unrelated to VLA.
Its easy to say, but I have long been fully satisfied that the board and CEO are singularly focused on engaging with prospective partners. However, other than comparative trials with a couple of major pharma co's (nothing terribly earth-shattering about this as an outcome) there is little tangible evidence to demonstrate the success or otherwise of these engagements.
IMO, evidence from the sector strongly suggests that shareholders and the market will not be told anything of substance until the company has a binding in-principle agreement for shareholder consideration.
So shareholders have little option but sit and wait for a substantive transaction or liquidity event to be announced.
Perhaps when faith wavers we can take small comfort in knowing the board and CEO are handsomely motivated to deliver.
- Forums
- ASX - By Stock
- VLA
- Roth Report
Roth Report, page-45
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online